A new bill before Congress would amend the COINS Act to extend additional licensing restrictions to Chinese biotechnology, according to the piece. The proposal would also include mechanisms that would affect how U.S. stakeholders handle clinical-trial data from China. The article focuses on the debate among policymakers and regulators about whether the FDA should disregard clinical-trial evidence generated in China. It frames the question as balancing patient access to faster and cheaper therapies against national security concerns tied to technology-transfer risk. For biotech firms operating across borders, the development raises the stakes for evidence packages and regulatory strategy, especially where trials are conducted in China and the assets depend on global enrollment and documentation standards.